Archives
Dutasteride Workflow for Prostate Cancer Research
2026-09-17
Build reproducible androgen-modulation experiments with Dutasteride, a dual 5-alpha-reductase inhibitor, across DHT, viability, and apoptosis endpoints. This workflow combines practical formulation guidance with assay controls and a reference-informed strategy for separating direct cellular effects from downstream biology.
ECE-1c, CK2, and Cisplatin Resistance in Lung Cancer
2026-09-16
A 2024 Biological Research study identifies Lys-6-dependent stabilization of ECE-1c as a driver of stemness, cisplatin resistance, and invasiveness in NSCLC cells. Its use of silmitasertib links CK2 activity to this phenotype while supporting a non-canonical, ET-1-independent mechanism that requires further validation in vivo.
EPI-001: Androgen Receptor N-Terminal Domain Workflow
2026-09-16
EPI-001 enables researchers to interrogate androgen receptor signaling beyond the ligand-binding domain, with applications spanning prostate cancer and AR/ARv7-positive TNBC models. This practical guide connects mechanism to dose-response, transcriptional, viability, and metastasis assays while emphasizing formulation and interpretation controls.
P2RX1, CaMKII, and Mitochondrial Apoptosis in Ph+ ALL
2026-09-15
A 2025 study identifies P2RX1 as a regulator of tyrosine kinase inhibitor response in Philadelphia chromosome-positive acute lymphoblastic leukemia, linking calcium dysregulation and CaMKII activation to PI3K/Akt suppression and mitochondrial apoptosis. The findings provide a mechanistic framework for studying treatment sensitivity, while the cell-line and perturbation-based design requires further validation in patient samples and in vivo models.
Measuring Drug Response Beyond Cell Viability
2026-09-15
Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent dimensions of anticancer drug response. The work provides a framework for interpreting in vitro experiments more precisely by considering response magnitude, composition, and timing rather than relying on a single viability endpoint.
Kidney-Targeted mRNA Nanoparticles: Study Insights
2026-09-14
This 2024 Pace University dissertation examines whether excipients can overcome a loading-capacity limit in polymeric mesoscale nanoparticles intended for kidney delivery. Its formulation strategy combines encapsulation, particle-size quality control, cytotoxicity, pharmacokinetic, cellular uptake, and protein-expression assays to evaluate whether higher mRNA loading remains compatible with functional delivery.
DDRGK1 UFMylation Controls STAT3 in Osteoarthritis
2026-09-14
The reference study identifies DDRGK1-mediated UFMylation as a regulatory brake on STAT3 phosphorylation, nuclear translocation, and inflammatory cartilage degeneration. By combining human cartilage analysis, conditional mouse genetics, multi-omics, protein-interaction assays, and pharmacological rescue, the authors connect loss of DDRGK1 activity with osteoarthritis progression and nominate STAT3 inhibition as a mechanistically supported intervention.
Fulvestrant: ERα Degradation for Causal Assays
2026-09-13
Fulvestrant (ICI 182,780) is more than an estrogen antagonist: it is a pharmacological tool for separating ERα signaling, MDM2 protein degradation, and chemotherapy response. This article translates receptor-selective evidence into practical assay decisions while defining the limits of cross-domain interpretation.
SEMA3E, β-Catenin, and Beige Fat Thermogenesis
2026-09-12
A 2026 study identifies SEMA3E as a positive regulator of beige adipocyte differentiation and non-shivering thermogenesis in mice, linking its activity to mitochondrial respiration and Wnt/β-catenin signaling. The work combines adipose-tissue perturbation, transplantation, transcriptomics, and metabolic assays to define a mechanistic framework for studying thermogenic fat biology.
Dorsomorphin 2HCl: AMPK Inhibitor Guide
2026-09-11
Dorsomorphin 2HCl is a preclinical AMPK inhibitor that also suppresses BMP receptor signaling. Its dual activity supports mechanistic studies of hepatic lipid metabolism, osteogenic differentiation, hepcidin expression regulation, and iron homeostasis research.
IBDV VP3 Disrupts IRF7 to Promote Viral Replication
2026-09-11
A 2025 Frontiers study identifies IBDV VP3 as an antagonist of chicken IRF7-mediated type I interferon signaling. Using infection, gene perturbation, proteasome inhibition, and protein-interaction analyses, the authors show that VP3 promotes IRF7 degradation and thereby supports viral replication.
Estradiol, ER Signaling, and T-Cell Recovery After Shock
2026-09-10
This study identifies endoplasmic reticulum stress as a mechanistic link between hemorrhagic shock and impaired splenic CD4+ T-lymphocyte function. Pharmacological evidence indicates that estradiol restores T-cell proliferation and cytokine production mainly through ERα and GPR30-associated signaling, rather than ERβ, by reducing stress responses.
20-HETE–TRPV1 Signaling in Chronic Dermatitis
2026-09-10
The reference study identifies a peripheral mechanism by which elevated 20-HETE activates TRPV1 on sensitized MrgprA3+ sensory neurons and converts normally painful stimulation into itch-related allokinesis in chronic dermatitis. Its combination of behavioral, neuronal, metabolomic, and pharmacological experiments supports 20-HETE–TRPV1–MrgprA3 signaling as a mechanistic target for chronic itch research.
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-09-09
This study develops a localized, nonviral strategy for bladder cancer by delivering chemically modified CDKN1A/p21 mRNA in lipid nanoparticles through intravesical administration. The findings connect transient nuclear p21 restoration with cell-cycle suppression, DNA-damage signaling, apoptosis, and reduced orthotopic tumor growth while limiting systemic exposure.
Abiraterone Acetate in 3D Prostate Cancer Models
2026-09-09
A translational framework for using Abiraterone acetate as a CYP17 inhibitor in patient-derived prostate cancer spheroids, with emphasis on mechanism, exposure control, model limitations, and strategic assay design.
610 records 8/41 page Previous Next First page 上5页 678910 下5页 Last page